



(43) International Publication Date
20 March 2014 (20.03.2014)

(10) International Publication Number
WO 2014/043087 A1

(51) International Patent Classification:
C07D 487/00 (2006.01)

(21) International Application Number:
PCT/US2013/058941

(22) International Filing Date:
10 September 2013 (10.09.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/701,250 14 September 2012 (14.09.2012) US

(71) Applicant: **DOW AGROSCIENCES LLC** [US/US];
9330 Zionsville Road, Indianapolis, IN 46268 (US).

(72) Inventors: **BLAND, Douglas C.**; 331 Broadhead Drive,
Midland, MI 48642 (US). **ROTH, Gary**; 1250 East Stewart
Road, Midland, MI 48640 (US). **BOTT, Craig**; 2787
E. Elm Rd., Clare, MI 48617 (US). **HAMILTON, Chris-**
topher T.; 3708 East Acorn Lane, Midland, MI 48642
(US). **NEUMAN, Joseph**; 3369 Greystone Place, Midland,
MI 48642 (US).

(74) Agent: **ASAM, Michael**; Dow AgroSciences LLC, 9330
Zionsville Rd, Indianapolis, Indiana 46268 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

(54) Title: PROCESS FOR THE PREPARATION OF 2-AMINO-5,8-DIMETHOXY[1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE
FROM 4-CHLORO-2,5-DIMETHOXYPYRIMIDINE

(57) Abstract: 2-Amino-5,8-dialkoxy[1,2,4]-triazolo[1,5-c]pyrimidines are manufactured from 4-chloro-2,5-dialkoxyprymidines in
a process that avoids hydrazine and cyanogen halide.



WO 2014/043087 A1

PROCESS FOR THE PREPARATION OF 2-AMINO-5,8-DIMETHOXY[1,2,4]TRIAZOLO[1,5-*c*]PYRIMIDINE FROM 4-CHLORO-2,5-DIMETHOXYPYRIMIDINE

Background

5 Provided herein are processes for the preparation of 2-amino-5,8-dimethoxy[1,2,4]triazolo[1,5-*c*]pyrimidine from 4-chloro-2,5-dimethoxypyrimidine.


U.S. Patent 6,005,108 describes certain substituted 2-amino-5,8-dialkoxy[1,2,4]-triazolo[1,5-*c*]pyrimidine compounds and their use as intermediates for the preparation of sulfonamide herbicides. 2-Amino-5,8-dimethoxy[1,2,4]triazolo[1,5-*c*]pyrimidine is a useful
10 intermediate for the preparation of penoxsulam. *Monatsh. Chem.* **1983**, 114, 789 describes the preparation of certain (amino)carbonothioylcarbamates followed by their reaction with hydroxylamine and subsequent cyclization to [1,2,4]triazolo[1,5-*a*]pyrimidin-2-amines. WO 2009/047514 A1 describes the preparation of certain (amino)carbonothioylcarbamates followed by their reaction with hydroxylamine and subsequent cyclization to
15 [1,2,4]triazolo[1,5-*a*]pyridine and [1,2,4]triazolo[1,5-*c*]pyrimidine compounds. US 6,559,101 B2 describes the preparation of certain (amino)carbonothioylcarbamates followed by their reaction with hydroxylamine and subsequent cyclization to pyrimidine-substituted [1,2,4]triazolo[1,5-*a*]pyrimidin-2-amines.

U.S. Patent 6,362,335 B2 describes the production of 2-amino-5,8-dimethoxy[1,2,4]-
20 triazolo[1,5-*c*]pyrimidine from 2,4-dichloro-5-methoxypyrimidine or 4-chloro-2,5-dimethoxypyrimidine in a multistep process that involves both hydrazine and a cyanogen halide. Hydrazine presents a severe explosion hazard and is toxic by ingestion, inhalation and skin adsorption. It is classified as a carcinogen and has a threshold limit value (TLV) of 0.1 ppm in air. Cyanogen halides are highly irritating and very poisonous. It would be
25 advantageous to produce 2-amino-5,8-dialkoxy[1,2,4]triazolo[1,5-*c*]pyrimidines efficiently and in high yield by a manufacturing process that avoids hydrazine and cyanogen halide.

Summary

Provided herein are processes for the preparation of 2-amino-5,8-dialkoxy[1,2,4]-triazolo[1,5-*c*]pyrimidine from 4-chloro-2,5-dialkoxypyrimidines. More particularly,

provided herein are processes for the preparation of 2-amino-5,8-dialkoxy[1,2,4]-triazolo[1,5-*c*]pyrimidines of the formula (I),




in which

5 R represents C₁-C₄ alkyl


which comprises:

i) contacting a 4-chloro-2,5-dialkoxypyrimidine of the formula




in which R is as previously defined

10 with a salt of cyanamide in a polar aprotic solvent to provide a 2,5-dialkoxy-4-cyanoaminopyrimidine of the formula



in which R is as previously defined;

15 ii) contacting the 2,5-dialkoxy-4-cyanoaminopyrimidine with either hydroxylamine as a free base or hydroxylamine salt in the presence of a base to provide a 2,5-dialkoxy-4-hydroxyguanidinylpyrimidine of the formula




in which R is as previously defined; and

- iii) cyclizing the 2,5-dialkoxy-4-hydroxyguanidinylpyrimidine by treating with an alkyl chloroformate to provide the 2-amino-5,8-dialkoxy[1,2,4]triazolo[1,5-*c*]-pyrimidine (I).


In another embodiment of the invention, the 2,5-dialkoxy-4-cyanoaminopyrimidine can be converted into the corresponding 2-amino-5,8-dialkoxy[1,2,4]-triazolo[1,5-*c*]-pyrimidine by combining steps ii) and iii) without isolating the 2,5-dialkoxy-4-hydroxyguanidinylpyrimidine.

- Another embodiment of the invention comprises a 2,5-dialkoxy-4-cyanoaminopyrimidine of the formula



in which R represents C₁-C₄ alkyl.

- A further embodiment of the invention comprises a 2,5-dialkoxy-4-hydroxy-guanidinylpyrimidine of the formula




in which R represents C₁-C₄ alkyl.

The material may exist as a pair of geometric isomers (*E* and *Z*), as well as in various tautomeric forms.

Detailed Description

The term alkyl and derivative terms such as alkoxy, as used herein refer to straight chain or branched chain groups. Typical alkyl groups are methyl, ethyl, propyl, 1-methyl-ethyl, butyl, 1,1-dimethylethyl and 1-methylpropyl. Methyl and ethyl are often preferred.

- 5 The present invention concerns the preparation of 2-amino-5,8-dialkoxy[1,2,4]-triazolo[1,5-*c*]pyrimidines from 4-chloro-2,5-dialkoxypyrimidines.



- 10 The first step (*a*) concerns the conversion of a 4-chloro-2,5-dialkoxypyrimidine (1) in which R represents C₁-C₄ alkyl to a 2,5-dialkoxy-4-cyanoaminopyrimidine (2). This is accomplished using at least one equivalent of a salt of cyanamide in a polar aprotic solvent. In some embodiments, 1 to about 2.5 molar equivalents of the salt of cyanamide are employed. The salt of cyanamide, in certain embodiments, is an alkali metal salt such as sodium or potassium or an alkaline earth metal salt such as magnesium or calcium.
- 15 In some embodiments, the salt is sodium hydrogen cyanamide. Exemplary polar aprotic solvents include acetonitrile and amides such as *N*-methyl-2-pyrrolidinone (NMP). It is also possible to perform the reaction in the presence of additional diluents such as crown ethers and glycol ethers, provided those diluents do not interfere with the desired reaction and are chemically inert to the reactants. The 4-chloro-2,5-dialkoxypyrimidine and the salt of cyanamide are
- 20

reacted at a temperature from about 0 °C to about 60 °C. The product is isolated by conventional techniques, such as by filtration of a precipitated or crystallized material.

In some embodiments, sodium hydrogen cyanamide is suspended in NMP and then treated with the appropriate amount of 4-chloro-2,5-dimethoxypyrimidine. After heating, the reaction mixture is cooled and neutralized with acid to precipitate 2,5-dimethoxy-4-cyanoaminopyrimidine which is collected by filtration and dried.

The second step (b) concerns the conversion of the 2,5-dialkoxy-4-cyanoaminopyrimidine (2) to the 2,5-dialkoxy-4-hydroxyguanidinylpyrimidine (3). This is accomplished using at least an equivalent of either hydroxylamine as a free base or an hydroxylamine salt and a base, such as sodium or potassium carbonate, sodium or potassium hydroxide or a trialkylamine, in a polar solvent. In some embodiments, trialkylamines, such as triethylamine, are utilized as auxiliary bases. In some embodiments, 2 equivalents of hydroxylamine and base are utilized in this reaction. The reactants are, in some embodiments, suspended in a polar solvent and the mixture is stirred at a temperature from about 0 °C to about 80 °C. The polar solvent may be either protic or aprotic. Exemplary protic polar solvents include alcohols such as methanol and exemplary aprotic polar solvents include esters or nitriles such as ethyl acetate or acetonitrile. The product mixture is cooled and treated with water and the 2,5-dialkoxy-4-hydroxyguanidinylpyrimidine is isolated by conventional techniques, such as collection by filtration and drying. The material may exist as an *E/Z* isomeric mixture and/or in various tautomeric forms.

In some embodiments, 2,5-dimethoxy-4-cyanoaminopyrimidine and the hydroxylamine salt are slurried in the polar solvent and triethylamine is added. The reaction mixture is stirred at about 45 °C for several hours, treated with water and the 2,5-dimethoxy-4-hydroxyguanidinylpyrimidine is collected by filtration and dried.

The third step (c) concerns the conversion of the 2,5-dialkoxy-4-hydroxyguanidinylpyrimidine (3) to the 2-amino-5,8-dialkoxy[1,2,4]triazolo[1,5-*c*]pyrimidine (I). This is accomplished using at least an equivalent of a C₁-C₄ alkyl chloroformate and a base, such as sodium or potassium carbonate, sodium or potassium hydroxide or a trialkylamine, in a polar aprotic solvent. In some embodiments, trialkylamines, such as triethylamine, are utilized as the auxiliary bases. In some embodiments, methyl chloroformate is utilized. In some embodiments, 2 equivalents of alkyl

chloroformate and base are utilized in this reaction. The reactants are, in some embodiments, suspended in the polar aprotic solvent and the mixture is stirred at a temperature from about 45 °C to about 100 °C. Exemplary polar aprotic solvents include esters or nitriles such as ethyl acetate or acetonitrile. The product mixture is cooled and treated with water and the 2-amino-5,8-dialkoxy[1,2,4]triazolo[1,5-*c*]pyrimidine (I) is isolated by conventional techniques, such as collection by filtration and drying.

In some embodiments, 2,5-dimethoxy-4-hydroxyguanidinylpyrimidine and methyl chloroformate are slurried in the polar solvent and triethylamine is added. The reaction mixture is stirred at about 80 °C for several hours, treated with water and the 2-amino-5,8-dimethoxy[1,2,4]-triazolo[1,5-*c*]pyrimidine is collected by filtration and dried.


In some embodiments, steps *b* and *c* are combined and the isolation of the 2,5-dialkoxy-4-hydroxyguanidinylpyrimidine (*b* + *c*)' is not performed. When combining steps *b* and *c*, the reaction needs to be conducted in a polar aprotic solvent such as, for example, ethyl acetate or acetonitrile.

In some embodiments, 2,5-dimethoxy-4-cyanoaminopyrimidine and hydroxylamine hydrochloride are slurried in acetonitrile and triethylamine is added. The reaction mixture is stirred at about 45 °C for several hours and cooled to about 5 °C. With external cooling, an additional equivalent of triethylamine is added followed by methyl chloroformate. After briefly stirring at ambient temperature, the reaction mixture is stirred at reflux until completion and treated with water. The solid 2-amino-5,8-dimethoxy[1,2,4]-triazolo[1,5-*c*]pyrimidine is collected by filtration and dried.


The following examples are presented to illustrate the invention.

EXAMPLES

The described embodiments and following examples are for illustrative purposes and are not intended to limit the scope of the claims. Other modifications, uses, or combinations with respect to the compositions described herein will be apparent to a person of ordinary skill in the art without departing from the spirit and scope of the claimed subject matter.

Example 1. Preparation of 2,5-dimethoxy-4-cyanoaminopyrimidine (2)Step a:


To a 100 milliliter (mL) three-neck round bottom flask were added sequentially 7.8 grams (g) (121.53 millimole (mmol)) of sodium hydrogen cyanamide and 34.2 g of *N*-methyl-2-pyrrolidinone (NMP) in one portion, and the slurry mixture was cooled in an ambient temperature water bath. To this mixture was added 10.0 g (54.99 mmol) of 96% 4-chloro-2,5-dimethoxypyrimidine (**1**; CDMP) in one portion. The mixture was allowed to stir at ambient temperature (<20 °C). After 65 hours (h), 3.55 g (59.11 mmol) of glacial acetic acid was added in one portion and the internal pot temperature rose from 18 °C to 23 °C. This reaction slurry was pipetted over 87.1 g of crushed ice and the ice was allowed to melt. To this mixture was added 10.3 g of sodium chloride. The mixture was allowed to stand until the crushed ice was fully melted. Once melted, the cold slurry was suction filtered and the filter cake was washed with one 10 mL portion of water and then two 20-mL portions of water. The wet cake was isolated to afford 9.39 g (80.2% pure by NMR assay using benzyl acetate) of 2,5-dimethoxy-4-cyanoaminopyrimidine (**2**) as a light yellow solid mp 164-171 °C in 76% yield; ¹H NMR (DMSO-*d*₆, 400 MHz) δ 3.72 (s, 3H), 3.94 (s, 3H), 7.46 (s, 1H), 12.48 (br s, ~1H); ¹³C NMR (DMSO, 100 MHz) δ 55.21, 56.60, 116.20, 121.8 (br s), 138.9, 153.9, 162.6 (br s).

20 Example 2. Preparation of 2,5-dimethoxy-4-cyanoaminopyrimidine (2)Step a:


To a 100 mL three-neck round bottom flask were added sequentially 7.8 g (121.53 mmol) of sodium hydrogen cyanamide and then 34.2 g of *N*-methyl-2-pyrrolidinone (NMP) in one portion, and the slurry mixture was cooled in an ambient temperature water bath. To this mixture was added 10.0 g (54.99 mmol) of 96% 4-chloro-2,5-dimethoxypyrimidine (**1**; CDMP) in one portion. The mixture was allowed to stir at ambient temperature (<20 °C). After 48 hours (h), 3.78 g (62.95 mmol) of glacial acetic acid was added in one portion and the internal pot temperature rose from 19 °C to 23 °C. This reaction slurry was poured over 85 g of crushed ice and the ice was allowed to melt. To this mixture was added 10 g of sodium chloride. The mixture was allowed to stand for 16 minutes (min). Once melted, the cold slurry was suction filtered and the filter cake was washed with two 20-mL portions of water and a final 10 mL water wash. The wet cake transferred to a drying dish and allowed to air dry for 48 h to give 6.78 g (98.8% pure by NMR assay using benzyl acetate) of 2,5-dimethoxy-4-cyanoaminopyrimidine (**2**) as a light yellow solid in 68% yield. ¹H and ¹³C NMR spectra were identical to that reported in Example 1.

Example 3. Preparation of 2,5-dimethoxy-4-cyanoaminopyrimidine (**2**)


Step a:




4-Chloro-2,5-dimethoxypyrimidine (CDMP; 15 g, 0.086 mol) was dissolved in *N*-methyl-2-pyrrolidinone (NMP; 62.5 g) at ambient temperature. Sodium hydrogen cyanamide (12.1 g, 2.2 eq) was added all at once, and the mixture was heated to 50 °C with stirring for 2.5 h. The resulting slurry was cooled to 25 °C, and 150 mL of water was added. Concentrated hydrochloric acid was added drop-wise until a pH of 5.5 was reached. The thick slurry was filtered and washed twice with 10 mL of water to afford 2,5-dimethoxy-4-cyanoamino-pyrimidine (**2**) as a white solid (11.83 g, 76% yield).

Example 4. Preparation of 2-amino-5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidine (I)Step (b + c)':

To a 25 mL three-neck round bottom flask were added 1.11 g (5.55 mmol) of 90 wt%
5 2,5-dimethoxy-4-cyanoaminopyrimidine (**2**), 463 mg (6.66 mmol) of hydroxylamine
hydrochloride, and 9.8 g of acetonitrile. To this mixture was added 681 mg (6.72 mmol) of
triethylamine in one portion. The reaction mixture was heated to a gentle reflux (~45 °C) for
2 h. The reaction mixture was cooled in an ice water bath to about 5.8 °C at which time an
additional 716 mg (7.08 mmol) of triethylamine was added in one portion. To this mixture
10 was added 662 mg (7.01 mmol) of methyl chloroformate in one portion at which time the
internal reaction temperature rose from 5.8 °C to 12.1 °C. The ice water bath was removed
and the mixture was stirred at ambient temperature for 1 h and then at reflux (~76 °C) for
about 3 h. The reaction mixture was cooled to ambient temperature and an additional 100 µL
of triethylamine was added to adjust the reaction pH to about 7-8. To this mixture was added
15 11.3 g of water; the mixture was transferred to a 100 mL round bottom flask; and the
acetonitrile was removed *in vacuo* at 60 mm Hg and 30 °C. The aqueous slurry was then
suction filtered over a medium glass frit and the residue from the flask was transferred with ~
2 g of water. After the cake de-liquored, another 1 g displacement water wash was passed
through the cake. After suction air drying the cake for 30 min, the mixture was allowed to
20 dry over a nitrogen pad overnight. This afforded 588 mg (~97% pure by liquid
chromatography (LC) analysis) of 2-amino-5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidine
(**I**) as a light yellow solid in 52.8% yield from starting 2,5-dimethoxy-4-
cyanoaminopyrimidine (**2**). ¹H NMR (DMSO-*d*₆, 400 MHz) δ 3.90 (s, 3H), 4.06 (s, 3H), 6.28
(br s, 2H), 7.48 (s, 1H); ¹³C NMR (DMSO-*d*₆, 100 MHz) δ 55.37, 57.04, 123.07, 138.60,
25 143.73, 148.50, 166.02.

Example 5. Preparation of 2,5-dimethoxy-4-hydroxyguanidnylpyrimidine (3)Step b:

2,5-Dimethoxy-4-cyanoaminopyrimidine (CDMP; **2**; 10 g, 0.055 mol) and
 5 hydroxylamine hydrochloride (5.09 g, 1.33 eq) were dispersed in methanol (60 ml).
 Triethylamine (7.59 g, 1.36 eq) was added and the slurry was heated to 45 °C with stirring.
 After 3 h at 45 °C, the slurry was cooled to room temperature and 60 mL of water was added
 followed by a 20 min digestion period. The slurry was filtered and the solid was dried to
 constant weight to afford 2,5-dimethoxy-4-hydroxyguanidnylpyrimidine (**3**) as a light tan
 10 solid (8.70 g, 74%). mp 159-168 °C (dec); ¹H NMR (DMSO-*d*₆, 400 MHz) δ 3.78 (s, 3H),
 3.82 (br s, 3H), 6.58 (br s, 2H), 7.85 (s, 1H), 8.66 (br s, 2H); ¹³C NMR (DMSO-*d*₆, 100 MHz)
 δ 54.01, 56.78, 136.51 (br s), 138.20, 150.50 (br s), 153.42 (br s), 157.69.

Example 6. Preparation of 2-amino-5,8-dimethoxy[1,2,4]triazolo[1,5-*c*]pyrimidine (I)Step c:


15

2,5-Dimethoxy-4-hydroxyguanidnylpyrimidine **3** (6 g, 0.028 mol) was dispersed in
 ethyl acetate (24 g). Ethyl chloroformate (3.7 g, 0.034 mol) was added to the slurry followed
 immediately by triethylamine (3.4 g, 0.034 mol). The slurry temperature rose to 48 °C and
 was further adjusted to 78 °C with applied heat. The viscosity of the slurry thinned and the
 20 solids went from white to a cream color as the slurry was heated. The conversion to **I** was
 slow, so water (20 g) was added at the 3 h mark. Water addition did not increase the rate of
 reaction, but after 9 h, the slurry contained 84.4% product **I** by LC analysis. The mixture was

cooled to 22 °C, filtered, and the wet-cake was washed with water (15 g). Drying afforded the 2-amino-5,8-dimethoxy[1,2,4]triazolo[1,5-*c*]pyrimidine (**I**) as a cream colored solid (3.57 g) that was 91.9% pure by LC area percent. The yield was 60% based on **3**.

WHAT IS CLAIMED IS:


1. A process for the preparation of 2-amino-5,8-dialkoxy[1,2,4]triazolo[1,5-*c*]-pyrimidines of the formula (I),



5 wherein R is C₁-C₄ alkyl


comprising:

i) contacting a 4-chloro-2,5-dialkoxypyrimidine of the formula




wherein R is as previously defined

10 with a salt of cyanamide in a polar aprotic solvent to provide a 2,5-dialkoxy-4-cyanoaminopyrimidine of the formula



in which R is as previously defined;

15 ii) contacting the 2,5-dialkoxy-4-cyanoaminopyrimidine with either hydroxylamine as a free base or hydroxylamine salt in the presence of a base to provide a 2,5-dialkoxy-4-hydroxyguanidinylpyrimidine of the formula



wherein R is as previously defined; and

iii) cyclizing the 2,5-dialkoxy-4-hydroxyguanidinylpyrimidine by treating with an alkyl chloroformate to provide the 2-amino-5,8-dialkoxy[1,2,4]triazolo[1,5-*c*]pyrimidine.

5 2. The process of claim 1, wherein R is CH₃.

3. The process of any of claims 1-2, wherein the 2,5-dialkoxy-4-hydroxyguanidinyl-pyrimidine of step ii) is used without isolation to prepare the 2-amino-5,8-dialkoxy[1,2,4]-triazolo[1,5-*c*]pyrimidine in step iii).

4. The process of any of claims 1-3, wherein the salt of cyanamide is an alkali
10 metal salt or alkaline earth metal salt.

5. The process of any of claims 1-4, wherein the salt of cyanamide is sodium hydrogen cyanamide.

6. The process of any of claims 1-5, wherein the polar aprotic solvent of (i) is acetonitrile or *N*-methyl-2-pyrrolidinone.

15 7. The process of any of claims 1-6, wherein (i) is performed at a temperature of from about 0 °C to about 60 °C.

8. The process of any of claims 1-7, wherein the free base of hydroxylamine salt of (ii) is a sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, or a trialkylamine salt.

20 9. The process of any of claims 1-8, wherein (ii) is performed in a polar solvent.

10. The process of claim 9, wherein the solvent is methanol, ethyl acetate, or acetonitrile.

11. The process of any of claims 1-10, wherein (ii) is performed at a temperature of from about 0 °C to about 80 °C.

12. The process of any of claims 1-11, wherein the alkylchloroformate of (iii) is a methyl chloroformate.

13. The process of any of claims 1-12, wherein (iii) is performed in the presence of a base.


5 14. The process of claim 13, wherein the base is sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, or triethylamine.

15. The process of any of claims 1-14, wherein (iii) is performed at a temperature of from about 45 °C to about 100 °C.

10 16. The process of any of claims 1-15, wherein (iii) is performed in a polar aprotic solvent.

17. The process of claim 16, wherein the solvent is ethyl acetate or acetonitrile.

18. A process for the preparation of 2-amino-5,8-dialkoxy[1,2,4]triazolo[1,5-*c*]-pyrimidines of the formula (I),




15 wherein R is C₁-C₄ alkyl

comprising:

cyclizing a 2,5-dialkoxy-4-hydroxyguanidinyipyrimidine


of the formula



wherein R is as previously defined;

by treating with an alkyl chloroformate to provide the 2-amino-5,8-dialkoxy[1,2,4]triazolo[1,5-*c*]pyrimidine.


19. The process of claim 18, wherein the 2,5-dialkoxy-4-hydroxyguanidinyipyrimidine is formed by contacting a 2,5-dialkoxy-4-cyanoaminopyrimidine of the formula



in which R is as previously defined


- with either hydroxylamine as a free base or hydroxylamine salt in the presence of a base to provide a 2,5-dialkoxy-4-hydroxyguanidinyipyrimidine.

20. The process of claim 19, wherein the the 2,5-dialkoxy-4-hydroxyguanidinyipyrimidine is formed by contacting a 4-chloro-2,5-dialkoxy-4-hydroxyguanidinyipyrimidine of the formula




- wherein R is as previously defined
- with a salt of cyanamide in a polar aprotic solvent.

21. A compound of the formula



in which R represents C₁-C₄ alkyl.

22. A compound of the formula



in which R represents C₁-C₄ alkyl.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 13/58941

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07D 487/00 (2013.01)

USPC - 544/263

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - C07D 487/00 (2013.01)

USPC - 544/263

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Patents, non-patent literature, search term limited

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Patbase (pgpb, uspt, usoc, epab, jpab, dwpi, tdbd), Dialog Proquest (npl), Google Patents (pl, npl), Google scholar (pl, npl), WIPO (pl);
Search Terms: chloroformate, pyrimidine, guanidine, cyanamide, cyanoaminopyrimidine, triazolo, dimethoxy, dialkoxy, cyano, hydroxylamine, cyclization, cyclisation, chloro, bland, douglas, dow, agro, hydrazine, ami

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,362,335 B2 (EMONDS, et al.) 26 March 2002 (26.03.2002) entire document, especially col 1, ln 28-32, 66-col 2, ln 12, 15-26	1-3, 18-22
Y	Bell, Bruce M., et al. "Application of the tislser triazolopyrimidine cyclization to the synthesis of a crop protection agent and an intermediate." Organic process research & development 10.6 (2006): 1167-1171	1-3, 18-22
A	US 8,143,395 B2 (Bott et al.) 27 March 2012 (27.03.2012) entire document	1-3, 18-22

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

30 December 2013 (30.12.2013)

Date of mailing of the international search report

22 JAN 2014

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 13/58941

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 4-17
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

摘要

本发明提供了由 4-氯-2,5-二烷氧基嘧啶制备 2-氨基-5,8-二烷氧基[1,2,4]-三唑并[1,5-c]嘧啶的方法，该方法避免了肼和氰卤化物。